Executive officer

Birgit Girshick

Corporate Executive Vice President and Chief Operating Officer (Chief Executive Officer effective May 5, 2026)·Charles River Laboratories International, Inc.

About

B

i

r

g

i

t

G

i

r

s

h

i

c

k

i

s

C

o

r

p

o

r

a

t

e

E

x

e

c

u

t

i

v

e

V

i

c

e

P

r

e

s

i

d

e

n

t

a

n

d

C

h

i

e

f

O

p

e

r

a

t

i

n

g

O

f

f

i

c

e

r

o

f

C

h

a

r

l

e

s

R

i

v

e

r

L

a

b

o

r

a

t

o

r

i

e

s

a

n

d

w

i

l

l

b

e

a

p

p

o

i

n

t

e

d

C

h

i

e

f

E

x

e

c

u

t

i

v

e

O

f

f

i

c

e

r

e

f

f

e

c

t

i

v

e

M

a

y

5

,

2

0

2

6

.

S

h

e

j

o

i

n

e

d

t

h

e

C

o

m

p

a

n

y

i

n

1

9

8

9

a

n

d

o

r

i

g

i

n

a

l

l

y

h

e

l

d

p

o

s

i

t

i

o

n

s

o

f

i

n

c

r

e

a

s

i

n

g

r

e

s

p

o

n

s

i

b

i

l

i

t

y

i

n

i

t

s

R

M

S

G

e

r

m

a

n

y

a

n

d

A

v

i

a

n

V

a

c

c

i

n

e

b

u

s

i

n

e

s

s

e

s

.

I

n

2

0

0

4

s

h

e

w

a

s

p

r

o

m

o

t

e

d

t

o

G

e

n

e

r

a

l

M

a

n

a

g

e

r

o

f

t

h

e

A

v

i

a

n

V

a

c

c

i

n

e

S

e

r

v

i

c

e

s

b

u

s

i

n

e

s

s

,

w

a

s

n

a

m

e

d

E

x

e

c

u

t

i

v

e

D

i

r

e

c

t

o

r

,

R

M

S

P

r

o

c

e

s

s

I

m

p

r

o

v

e

m

e

n

t

i

n

2

0

0

9

,

a

n

d

C

o

r

p

o

r

a

t

e

V

i

c

e

P

r

e

s

i

d

e

n

t

,

G

l

o

b

a

l

B

i

o

p

h

a

r

m

a

c

e

u

t

i

c

a

l

S

e

r

v

i

c

e

s

i

n

2

0

1

0

.

I

n

2

0

1

3

s

h

e

w

a

s

p

r

o

m

o

t

e

d

t

o

C

o

r

p

o

r

a

t

e

S

e

n

i

o

r

V

i

c

e

P

r

e

s

i

d

e

n

t

,

R

e

s

e

a

r

c

h

M

o

d

e

l

s

a

n

d

B

i

o

l

o

g

i

c

s

T

e

s

t

i

n

g

S

o

l

u

t

i

o

n

s

,

a

n

d

i

n

2

0

1

6

l

e

d

t

h

e

i

n

t

e

g

r

a

t

i

o

n

o

f

W

I

L

R

e

s

e

a

r

c

h

i

n

t

o

t

h

e

S

a

f

e

t

y

A

s

s

e

s

s

m

e

n

t

b

u

s

i

n

e

s

s

a

n

d

a

s

s

u

m

e

d

t

h

e

r

o

l

e

o

f

C

o

r

p

o

r

a

t

e

S

e

n

i

o

r

V

i

c

e

P

r

e

s

i

d

e

n

t

,

G

l

o

b

a

l

D

i

s

c

o

v

e

r

y

S

e

r

v

i

c

e

s

.

I

n

F

e

b

r

u

a

r

y

2

0

1

8

s

h

e

w

a

s

a

p

p

o

i

n

t

e

d

C

o

r

p

o

r

a

t

e

E

x

e

c

u

t

i

v

e

V

i

c

e

P

r

e

s

i

d

e

n

t

,

G

l

o

b

a

l

D

i

s

c

o

v

e

r

y

a

n

d

S

a

f

e

t

y

A

s

s

e

s

s

m

e

n

t

,

a

d

d

i

n

g

r

e

s

p

o

n

s

i

b

i

l

i

t

y

f

o

r

t

h

e

B

i

o

l

o

g

i

c

s

S

o

l

u

t

i

o

n

s

a

n

d

A

v

i

a

n

V

a

c

c

i

n

e

S

e

r

v

i

c

e

s

b

u

s

i

n

e

s

s

i

n

A

u

g

u

s

t

2

0

1

8

.

I

n

N

o

v

e

m

b

e

r

2

0

2

1

s

h

e

w

a

s

p

r

o

m

o

t

e

d

t

o

C

h

i

e

f

O

p

e

r

a

t

i

n

g

O

f

f

i

c

e

r

o

f

t

h

e

C

o

m

p

a

n

y

,

a

d

d

i

n

g

t

h

e

R

e

s

e

a

r

c

h

M

o

d

e

l

s

a

n

d

S

e

r

v

i

c

e

s

,

M

i

c

r

o

b

i

a

l

S

o

l

u

t

i

o

n

s

a

n

d

C

D

M

O

b

u

s

i

n

e

s

s

e

s

a

s

w

e

l

l

a

s

t

h

e

G

l

o

b

a

l

I

n

f

o

r

m

a

t

i

o

n

T

e

c

h

n

o

l

o

g

i

e

s

g

r

o

u

p

t

o

h

e

r

r

e

s

p

o

n

s

i

b

i

l

i

t

i

e

s

.

S

i

n

c

e

2

0

2

3

s

h

e

h

a

s

a

l

s

o

h

a

d

g

e

n

e

r

a

l

o

v

e

r

s

i

g

h

t

o

f

t

h

e

C

o

r

p

o

r

a

t

e

S

a

l

e

s

a

n

d

M

a

r

k

e

t

i

n

g

t

e

a

m

a

n

d

t

h

e

C

o

r

p

o

r

a

t

e

a

n

d

E

x

t

e

r

n

a

l

A

f

f

a

i

r

s

f

u

n

c

t

i

o

n

.

I

n

J

a

n

u

a

r

y

2

0

2

6

,

t

h

e

B

o

a

r

d

a

n

n

o

u

n

c

e

d

a

l

e

a

d

e

r

s

h

i

p

t

r

a

n

s

i

t

i

o

n

p

l

a

n

a

n

d

u

n

a

n

i

m

o

u

s

l

y

a

p

p

o

i

n

t

e

d

M

s

.

G

i

r

s

h

i

c

k

a

s

t

h

e

n

e

x

t

C

h

i

e

f

E

x

e

c

u

t

i

v

e

O

f

f

i

c

e

r

,

c

o

n

c

u

r

r

e

n

t

w

i

t

h

M

r

.

F

o

s

t

e

r

'

s

p

l

a

n

n

e

d

r

e

t

i

r

e

m

e

n

t

,

e

f

f

e

c

t

i

v

e

M

a

y

5

,

2

0

2

6

.

S

h

e

w

a

s

a

l

s

o

n

o

m

i

n

a

t

e

d

t

o

b

e

c

o

m

e

a

d

i

r

e

c

t

o

r

o

f

t

h

e

C

o

m

p

a

n

y

e

f

f

e

c

t

i

v

e

a

t

t

h

e

2

0

2

6

A

n

n

u

a

l

M

e

e

t

i

n

g

o

f

S

h

a

r

e

h

o

l

d

e

r

s

.

Since 1989
Age 56
Tenure 37 yrs

Also at Charles River Laboratories International, Inc.

JF James C. Foster Chair, President and Chief Executive Officer NA Nancy C. Andrews Director (Executive Vice President and Chief Scientific Officer, Boston Children's Hospital) SB Steven Barg Director (Global Co-Head of Engagement, Elliott Investment Management L.P.) AC Abraham Ceesay Director (Chief Executive Officer, Rapport Therapeutics) ME Mark Enyedy Director (Former President and Chief Executive Officer, ImmunoGen, Inc.) PG Paul Graves Director (Former Chief Executive Officer, Rio Tinto Lithium)

Roles

Organization Role Dates Details
Charles River Laboratories International, Inc. Corporate Executive Vice President and Chief Operating Officer (Chief Executive Officer effective May 5, 2026) 1989–present Current role
Charles River Laboratories International, Inc. Positions in RMS Germany and Avian Vaccine businesses 1989 Joined the Company in 1989 and held positions of increasing responsibility.
Charles River Laboratories International, Inc. General Manager, Avian Vaccine Services 2004
Charles River Laboratories International, Inc. Executive Director, RMS Process Improvement 2009
Charles River Laboratories International, Inc. Corporate Vice President, Global Biopharmaceutical Services 2010
Charles River Laboratories International, Inc. Corporate Senior Vice President, Research Models and Biologics Testing Solutions 2013
Charles River Laboratories International, Inc. Corporate Senior Vice President, Global Discovery Services 2016 Also led the integration of WIL Research into the Safety Assessment business in 2016.
Charles River Laboratories International, Inc. Corporate Executive Vice President, Global Discovery and Safety Assessment Feb 2018 Took on additional responsibility for Biologics Solutions and Avian Vaccine Services in August 2018.
Charles River Laboratories International, Inc. Chief Operating Officer Nov 2021 Added Research Models and Services, Microbial Solutions and CDMO businesses and the Global Information Technologies group; since 2023 also oversees Corporate Sales and Marketing and Corporate and External Affairs.
Charles River Laboratories Corporate Executive Vice President (Discovery, Safety Assessment, Biologics Testing Solutions, Avian Vaccine Services) 2018-2021
Charles River Laboratories Corporate Senior Vice President, Research Models and Biologics Testing Solutions 2013-2018
Charles River Laboratories Corporate Vice President, Global Biopharmaceutical Services 2010-2013

Related

Company Charles River Laboratories International, Inc. Company hub Person James C. Foster Chair, President and Chief Executive Officer Person Nancy C. Andrews Director (Executive Vice President and Chief Scientific Officer, Boston Children's Hospital) Person Steven Barg Director (Global Co-Head of Engagement, Elliott Investment Management L.P.) Person Abraham Ceesay Director (Chief Executive Officer, Rapport Therapeutics) Person Mark Enyedy Director (Former President and Chief Executive Officer, ImmunoGen, Inc.) Person Paul Graves Director (Former Chief Executive Officer, Rio Tinto Lithium) Person Reshema Kemps-Polanco Director (Executive Vice President and Chief Commercial Officer, Novartis US) Person George Llado, Sr. Director (Former Senior Vice President and Chief Information Officer, Alexion Pharmaceuticals, Inc.) Person Martin W. Mackay Director (Lead Independent Director; Co-Founder and Non-Executive Chair, Rallybio Corporation) Person Craig B. Thompson Director (President Emeritus and Former President and Chief Executive Officer, Memorial Sloan Kettering Cancer Center) Person Virginia M. Wilson Director (Retired Senior Executive Vice President and Chief Financial Officer, TIAA) Person Michael Knell Interim Chief Financial Officer, Corporate Senior Vice President, and Chief Accounting Officer Deal Charles River Laboratories International Agilux Laboratories 2016 Deal page Deal Charles River Laboratories International Argenta And Biofocus Cro Services Division Of Galapagos 2014 Deal page Deal Charles River Laboratories International Blue Stream Laboratories 2016 Deal page
Source: Charles River Laboratories International, Inc. SEC filings and official company website

See how VectorShift works for your firm

Request Demo